Oxford BioTherapeutics is Pioneering the Discovery of Novel Oncology Targets for Solid Tumours

OBT076 is an antibody-drug conjugate currently in Phase 1b clinical trials. It employs a potential dual mechanism of action, not only directly targeting cancer cells but also re-engaging the patient’s immune system. By depleting immunosuppressive dendritic cells, OBT076 has the potential to reactivate the immune system and promote the induction and activation of T-cells to enhance the anti-tumour response. Balstilimab is a fully human monoclonal antibody that targets anti-programmed death 1 (PD-1). It is being developed by Agenus for the treatment of cancer. OBT076 as monotherapy and in combination with balstilimab are currently being evaluated in a Phase 1b trial for patients with advanced solid tumours. The first patient was dosed in December 2019, the trial is conducted at centre's in US, Spain, France, Belgium, and Greece. The study aims to assess the clinical efficacy of the OBT076 in monotherapy and in combination with balstilimab in patients with solid tumours, including Non-Small Cell Lung Cancer and gastric cancer.